AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18602724
Drug: 11-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11-valent pneumococcal PD-conjugate study vaccine
Trial: 15629356
Drug: Hexavalent DTPa-HBV-IPV/Hib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexavalent DTPa-HBV-IPV/Hib vaccine
Trial: 12271279
Drug: Postoperative imiquimod
RxNorm normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Postoperative imiquimod 5% cream applied for 8 weeks
Trial: 12271279
Drug: Postoperative imiquimod
RxNorm normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Postoperative imiquimod 5% cream
Trial: 415643
Drug: Gold salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gold salt treatment
Trial: 21944654
Drug: Eurythmy therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eurythmy therapy (EYT)
Trial: 30856689
Drug: Zolpidem 5
RxNorm normalized name: zolpidem 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem 5 mg daily for 4 weeks
Trial: 15564167
Drug: piperacillin/tazobactam 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: piperacillin/tazobactam 4 g/500 mg every 8 hours
Trial: 15564167
Drug: imipenem/cilastatin 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: imipenem/cilastatin 500 mg/500 mg every 6 hours
Trial: 11745931
Drug: Interferon-alpha (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (3 MU three times weekly for 52 weeks)
Trial: 3499066
Drug: Pyridoxine HCl
RxNorm normalized name: PYRIDOXINE HCL
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyridoxine HCl 50 mg/d
Trial: 22631063
Drug: 24‐hour steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24‐hour steroid avoidance group (n=41)
Trial: 16985020
Drug: TSER, TSER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TSER, TSER 3R G>C, and TS 1494del6 variants
Trial: 12838195
Drug: Enteral glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteral glutamine supplementation (0.3 g/kg/day)
Trial: 29956215
Drug: Co-Crystal of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-Crystal of Tramadol-Celecoxib (CTC) 100 mg, 150 mg, and 200 mg administered orally
Trial: 25209520
Drug: Ozenoxacin 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozenoxacin 2% cream applied once daily (0.2 g per application)
Trial: 25209520
Drug: Ozenoxacin 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozenoxacin 2% cream applied twice daily (0.2 g per application, 12 h apart)
Trial: 19129749
Drug: Dapagliflozin 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 100 mg
Trial: 19129749
Drug: Dapagliflozin 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 25 mg
Trial: 22776824
Drug: Dapagliflozin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin (all doses)
Trial: 11601838
Drug: Trapidil 200
RxNorm normalized name: trapidil 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trapidil 200 mg
Trial: 9586849
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg Zolpidem (Zol)
Trial: 9586849
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg Diazepam (Dz)
Trial: 9586849
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg Oxazepam (Ox)
Trial: 9586849
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg Zopiclone (Zop)
Trial: 9586849
Drug: Ethanol (EOH;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (EOH; 0.65 + 0.35 g x kg(‐1))
Trial: 7989704
Drug: Ribavirin (800,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin (800, 1000, or 1200 mg/kg per day)
Trial: 2499922
Drug: Rioprostil 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rioprostil 100 micrograms twice daily
Trial: 26353424
Drug: 1 500
RxNorm normalized name: vit-B1 500 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 500 ml of Ringers lactate
Trial: 26353424
Drug: 500 ml
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml of 6% pentastarch
Trial: 26353424
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 250 ml of 6% pentastarch and 750 ml of Ringers lactate
Trial: 23291800
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg olanzapine daily for 8 weeks
Trial: 23291800
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg risperidone daily for 8 weeks
Trial: 8986916
Drug: Quinapril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril (20 mg single dose)
Trial: 3904382
Drug: Intracoronary streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary streptokinase (SK) therapy
Trial: 31054568
Drug: LIDO (lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIDO (lidocaine 1.5 mg/kg loading, 1.5 mg/kg/h infusion)
Trial: 31054568
Drug: DEX (dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX (dexmedetomidine 0.5 μg/kg loading, 0.4 μg/kg/h infusion)
Trial: 30107054
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis (e.g., fluoroquinolones)
Trial: 26778006
Drug: Long-term androgen
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term androgen deprivation therapy (ADT) (≥ 2 years)
Trial: 26778006
Drug: Short-term androgen
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term androgen deprivation therapy (ADT) (< 2 years)
Trial: 24240712
Drug: Prehospital cooling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prehospital cooling (infusion of up to 2 L of 4°C normal saline)
Trial: 18684310
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin (BTX)‐A injections into the upper limb
Trial: 1964751
Drug: Fragmin (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fragmin (low molecular weight heparin) subcutaneously (120 anti-FXa U/kg) twice daily
Trial: 1964751
Drug: Standard heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard heparin (SH) as continuous intravenous infusion (480 IU kg‐1 day‐1)
Trial: 2834482
Drug: Standard heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard heparin (SH)
Trial: 1964751
Drug: Fragmin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fragmin and Standard heparin (SH)
Trial: 29040012
Drug: ALLIC 2002
RxNorm normalized name: gallic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALLIC 2002 protocol treatment for patients with Down syndrome
Trial: 29040012
Drug: ALLIC 2002
RxNorm normalized name: gallic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALLIC 2002 protocol treatment for patients without Down syndrome
Trial: 18503774
Drug: Rosiglitazone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (4 mg/day for the first month and 8 mg/day thereafter; n = 32)
Trial: 12841927
Drug: Etodolac SR
RxNorm normalized name: Etodolac
DrugBank: Etodolac (DB00749)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etodolac SR (400 mg/day)
Trial: 27470088
Drug: Diclofenac (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (100 mg/day)
Trial: 10885603
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (methotrexate 100 mg/m2 and cisplatin 50 mg/m2 for 3 cycles at 2-week intervals)
Trial: 1408479
Drug: High titer
RxNorm normalized name: Immune Globulin (Human) containing high titers of West Nile virus antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High titer Edmonston-Zagreb vaccine at 5 to 6 months of age
Trial: 1408479
Drug: Standard titer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard titer Schwarz vaccine at 8 to 9 months of age
Trial: 1408479
Drug: High titer
RxNorm normalized name: Immune Globulin (Human) containing high titers of West Nile virus antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High titer Biken-CAM vaccine at 8 to 9 months of age
Trial: 4062396
Drug: Empirical antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical antibiotic therapy (trimethoprim-sulfamethoxazole and erythromycin)
Trial: 27729174
Drug: Vaccine stored
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine stored at elevated temperatures (25 °C for up to six months or 30 °C for three months)
Trial: 27729174
Drug: Cold-chain stored
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold-chain stored vaccine (2–8 °C)
Trial: 16048260
Drug: NEPP (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEPP (1 dwell amino acids, 1 dwell icodextrin, and two dwells bicarbonate/lactate-buffered glucose-based solution)
Trial: 10500056
Drug: Infliximab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (10 mg/kg every 8 weeks)
Trial: 8744663
Drug: Intravenous nalbuphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nalbuphine infusion (15 micrograms/kg/h)
Trial: 2531153
Drug: Nafarelin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafarelin (400 micrograms daily)
Trial: 2531153
Drug: Danazol (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol (600 mg daily)
Trial: 17463418
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 2.5 mg vitamin D
Trial: 11591229
Drug: Water-miscible retinyl
RxNorm normalized name: RETINYL PALMITATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water-miscible retinyl palmitate (112 mg)
Trial: 11591229
Drug: Oil-soluble retinyl
RxNorm normalized name: RETINYL PALMITATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oil-soluble retinyl palmitate (112 mg)
Trial: 11271260
Drug: Ganciclovir (DHPG)
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ganciclovir (DHPG) 3 mg/kg q 12 h for 2 weeks, plus CMV-hyperimmunglobulin (1 ml/kg per week for 6 weeks) if CMV+ donor
Trial: 3122967
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg in the morning
Trial: 28110919
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia (Xylocaine gauze applied for 2 minutes)
Trial: 25673087
Drug: LB30870 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LB30870 60 mg
Trial: 25673087
Drug: LB30870 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LB30870 120 mg
Trial: 25673087
Drug: LB30870 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LB30870 (various doses)
Trial: 25673087
Drug: LB30870 (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LB30870 (doses above 15 mg)
Trial: 25673087
Drug: LB30870 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LB30870 (60 mg)
Trial: 25673087
Drug: LB30870 (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LB30870 (up to 240 mg)
Trial: 24284841
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (40 mg and 20 mg)
Trial: 18444815
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of metronidazole under directly observed therapy
Trial: 16472979
Drug: 6% carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% carbohydrate (CHO) solution
Trial: 16472979
Drug: 6-g essential
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-g essential amino acid (EAA) mixture
Trial: 16472979
Drug: Combined CHO+EAA
RxNorm normalized name: G-CSF (CHO cell derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined CHO+EAA supplement
Trial: 14512130
Drug: 2 loratadine
RxNorm normalized name: Loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 loratadine 5‐mg tablets + ambroxol 30‐mg tablets (Formulation A)
Trial: 14512130
Drug: 1 loratadine
RxNorm normalized name: loratadine 1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 loratadine 10‐mg tablet (Formulation C)
Trial: 14512130
Drug: 2 ambroxol
RxNorm normalized name: AMBROXOL
DrugBank: Ambroxol (DB06742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ambroxol 30‐mg tablets (Formulation B)
Trial: 7924865
Drug: Preoperative parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative parenteral nutritional support (PNS) for 5 days, yielding 117 Kj.kg‐1.d‐1 of non‐protein calories and 0.15g.kg‐1.d‐1 of nitrogen.
Trial: 7924865
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with 5‐Fu at 8‐10mg.kg‐1.d‐1 for 5 days and mitomycin C at 6‐8mg.d‐1 on the first and fifth day.
Trial: 7924865
Drug: PNS plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PNS plus chemotherapy (5‐Fu and mitomycin C) as in Groups A and B.
Trial: 29132880
Drug: Rivaroxaban (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (5 mg twice a day)
Trial: 29132880
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg once a day)
Trial: 30488637
Drug: Antipsychotic dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic dose reduction strategy with evidence-based intensive recovery treatment (DRS+)
Trial: 30488637
Drug: Antipsychotic maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic maintenance treatment with evidence-based intensive recovery treatment (AMTx+)
Trial: 30488637
Drug: Antipsychotic dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic dose reduction strategy (DRS+)
Trial: 30488637
Drug: Antipsychotic maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic maintenance treatment (AMTx+)
Trial: 9147610
Drug: Idarubicin (Ida)
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Idarubicin (Ida) 10 mg/m2 given as a 3 min infusion
Trial: 9147610
Drug: Idarubicin (Ida)
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Idarubicin (Ida) 10 mg/m2 given as a 2 h infusion
Trial: 9147610
Drug: Idarubicin (Ida)
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Idarubicin (Ida) in combination with Cytosine arabinoside (Ara‐C, 1 g/m2)
Trial: 9147610
Drug: Idarubicin (Ida)
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Idarubicin (Ida) as prolonged infusion
Trial: 8345007
Drug: Single 300-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 300-mg dose of phenytoin at 08.00 hours
Trial: 8345007
Drug: Single 300-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 300-mg dose of phenytoin at 20.00 hours
Trial: 23471268
Drug: GSK249320 (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK249320 (1, 5, or 15 mg/kg per infusion)
Trial: 10752681
Drug: Prolonged tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged tamoxifen therapy
Trial: 8855856
Drug: Oral ferrous
RxNorm normalized name: ferrous fumarate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ferrous sulphate (650 mg twice daily)
Trial: 6828092
Drug: Metoprolol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (15 mg intravenously initially, then 200 mg daily for three months)
Trial: 25695295
Drug: Inhaled colistin/oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled colistin/oral ciprofloxacin
Trial: 25695295
Drug: Nebulized tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Nebulized tobramycin 300 mg/oral ciprofloxacin
Trial: 22110163
Drug: AM211 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AM211 200 mg once daily for 7 days
Trial: 22110163
Drug: AM211 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AM211 (various doses 100 to 600 mg)
Trial: 22110163
Drug: AM211 (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AM211 (multiple dosing)
Trial: 22110163
Drug: AM211 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AM211 (all doses)
Trial: 20889993
Drug: High-dose tirofiban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose tirofiban (25 μg/kg) in addition to acetylsalicylic acid, unfractionated heparin, and 600 mg clopidogrel.
Trial: 20889993
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in addition to acetylsalicylic acid, unfractionated heparin, and 600 mg clopidogrel.
Trial: 20889993
Drug: High-dose tirofiban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose tirofiban (25 μg/kg).
Trial: 11665396
Drug: 0.3% Flurbiprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% Flurbiprofen gel
Trial: 11665396
Drug: 0.3% Triclosan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% Triclosan gel
Trial: 7991885
Drug: Salmeterol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol (50 micrograms via metered dose inhaler, twice daily for 2 weeks)
Trial: 7991885
Drug: Theophylline (individually
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (individually dose‐titrated, twice daily for 2 weeks)
Trial: 2643845
Drug: Propranolol (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (120 to 160 mg daily)
Trial: 2643845
Drug: Verapamil (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (320 mg daily)
Trial: 20109380
Drug: Idrastin lymph‐draining
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idrastin lymph‐draining cream with elastocompressive therapy
Trial: 20109380
Drug: Elastocompressive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elastocompressive therapy only
Trial: 10809036
Drug: Orlistat, 120
RxNorm normalized name: Orlistat, 120 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat, 120 mg 3 times a day for 104 weeks
Trial: 8614396
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (CT) with lomustine (CCNU), vincristine, and prednisone for 1 year
Trial: 1600529
Drug: Propafenone at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone at 300 mg twice daily
Trial: 1600529
Drug: Hydroquinidine retard
RxNorm normalized name: Hydroquinidine
DrugBank: Hydroquinidine (DB15300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroquinidine retard 250 mg twice daily
Trial: 3904258
Drug: 5 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 micrograms ml‐1 hepatitis B vaccine
Trial: 3904258
Drug: 10 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 micrograms ml‐1 hepatitis B vaccine
Trial: 29958034
Drug: Multi-ingredient detoxification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-ingredient detoxification supplement (1,350 mg/serving)
Trial: 23400916
Drug: 5-minute infusion
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-minute infusion of ertapenem 1 g
Trial: 23400916
Drug: 30-minute infusion
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-minute infusion of ertapenem 1 g
Trial: 19837318
Drug: PES split
RxNorm normalized name: Ipomoea pes-caprae flowering top extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PES split crest implants
Trial: 19837318
Drug: unsplit alveolar
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: unsplit alveolar ridge implants
Trial: 17023212
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n=12), receiving no treatment
Trial: 7719108
Drug: Large doses
RxNorm normalized name: Largemouth bass
DrugBank: Largemouth bass (DB10976)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large doses of hyoscyamus, self made Retarded Recovery Pill and acupuncture
Trial: 7719108
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of traditional Chinese and Western medicine
Trial: 2643074
Drug: Dexamethasone (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (3 tablets of 4 mg each)
Trial: 2643074
Drug: Dextrose placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose placebo (identical in appearance, same dosage schedule)
Trial: 31405866
Drug: Azithromycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (1 g) plus piperaquine (960 mg) for three days
Trial: 31405866
Drug: Sulfadoxine-pyrimethamine (4,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadoxine-pyrimethamine (4,500 mg sulfadoxine plus 225 mg pyrimethamine, single dose)
Trial: 29017627
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g milk protein (MLK20)